Showing results (21-30 of 28) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Journal of Medical Economics|December 10, 2020
Identifying disability level in multiple sclerosis patients in a U.S.-based health plan claims databaseRegina Berkovich, Edward Fox, Annette Okai, et al.Annals of Clinical and Translational Neurology|September 24, 2025
Annual 12-Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell CompositionRegina Berkovich, Tilman Schneider-Hohendorf, Eric Baetscher, et al.Annals of Clinical and Translational Neurology|March 27, 2026
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial ParticipantsRalf Gold, Krzysztof W Selmaj, Regina Berkovich, et al.Multiple Sclerosis and Related Disorders|December 25, 2022
Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysisRegina Berkovich, Donald Negroski, Daniel Wynn, et al.Journal of Neurology|June 26, 2020
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223Brian Steingo, Yaser Al Malik, Ann D Bass, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2019
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studiesGiancarlo Comi, Raed Alroughani, Aaron L Boster, et al.CNS Drugs|July 26, 2020
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension StudyTjalf Ziemssen, Ann D Bass, Regina Berkovich, et al.Neurology. Clinical Practice|May 1, 2018
Effectiveness of alternative dose fingolimod for multiple sclerosisErin E Longbrake, Daniel Kantor, Siddharama Pawate, et al.Pageof 3